1. Home
  2. FABC vs BCDA Comparison

FABC vs BCDA Comparison

Compare FABC & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fabric.AI Inc. Common Stock

FABC

Fabric.AI Inc. Common Stock

N/A

Current Price

$2.29

Market Cap

15.0M

ML Signal

N/A

Logo BioCardia Inc.

BCDA

BioCardia Inc.

N/A

Current Price

$1.02

Market Cap

14.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FABC
BCDA
Founded
1997
N/A
Country
United States
United States
Employees
108
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.0M
14.1M
IPO Year
1999
2009

Fundamental Metrics

Financial Performance
Metric
FABC
BCDA
Price
$2.29
$1.02
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $15.50
AVG Volume (30 Days)
118.2K
★ 237.4K
Earning Date
11-13-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $4,579,745.00
$479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.10
$0.75
52 Week High
$4.57
$1.80

Technical Indicators

Market Signals
Indicator
FABC
BCDA
Relative Strength Index (RSI) 41.71 42.83
Support Level $2.10 $0.80
Resistance Level $3.01 $1.29
Average True Range (ATR) 0.15 0.09
MACD 0.02 -0.02
Stochastic Oscillator 44.74 7.67

Price Performance

Historical Comparison
FABC
BCDA

About FABC Fabric.AI Inc. Common Stock

Fabric.AI Inc is an infrastructure company building a suite of fabless semiconductor technologies to power AI factories - smart data centers optimized for producing intelligence at scale. The company's innovations include MicroLED-based optical interconnects and other system-critical technologies that enable faster, more efficient, and more scalable AI workloads. Its mission is to transform data centers into unified production systems for artificial intelligence.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: